Truist initiated coverage of Biomea Fusion with a Buy rating and $55 price target. The firm views Biomea as “an undervalued opportunity,” noting that its price target represents about 200% upside. Phase 1/2 data from lead drug in Type 2 Diabetes provides strong proof of concept and the firm’s key focus is on larger patient data set in the second half of 2024. In addition, proof of concept data in Type 1 Diabetes and further positive data updates in AML provides significant upside, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMEA:
- Biomea Fusion announces anticipated 2024 corporate milestones
- Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
- Biomea Fusion doses first patient with type 1 diabetes in COVALENT-112 trial
- Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
- Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
